Esperoct® - Especialidad Medicinal autorizada por el Ministerio de Salud. Certificado N° 59.382. Prospecto vigente aprobado por ANMAT (ver código QR)
Giangrande P, Andreeva T, Chowdary P, ct al. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A. Thromb Haemost. 2017; 117(02):252 261
Cafuir Land Kempton C. Current and emerging factor VIII replacement products for hemophilia A. Ther Adv Hem. 2017;8(10):303 313
Lentz SR. Kavalki K. Ktamroth R. et al. Turoccocog alpha pegol (N8~GP) in severe hemophilia A:. long term safety and efficacy in previously treated patients of all ages in the pathfinder8 study. Res Proct Thromb Haemosc 2022:6(2):e 12674
National Hemophilia Foundation. MASAC recommendations concerning prophylaxis~ #241. New York, NY: National Hemophilia Foundation; 2016.
Adynovate00 [p.:ickagc insert]. Westlake Village. CA: Baxter Healthcare Corpor ation; 2021. 8. Jivi" (package insert]. Whippany, NJ: Bayer HealthCare LLC: 2018.
Jivi" (package insert]. Whippany, NJ: Bayer HealthCare LLC: 2018.